Noninvasive <i>in vivo</i> cell tracking using molecular imaging: A useful tool for developing mesenchymal stem cell-based cancer treatment

Rajendran, Ramya Lakshmi; Jogalekar, Manasi P.; Gangadaran, Prakash; Ahn, Byeong‐Cheol

doi:10.4252/wjsc.v12.i12.1492

Cited by 10 publications

(7 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A combination of radionuclide-labelling and PET imaging is often used in clinical settings, but it can detect both dead and live cells giving an incorrect account of viable cells. MRI certainly offers an advantage by allowing MSC visualisation immediately after transplantation but there are issues such as signal dilution over time and the signal may not necessarily match with cell viability of transplanted cells due to non-specific particle uptake and signal retention by dead cells [ 168 ].…”

Section: Current State Hurdles Future Work and Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Iron Oxide Nanoparticles in Mesenchymal Stem Cell Detection and Therapy

Mehta

2022

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) exhibit regenerative and reparative properties. However, most MSC-related studies remain to be translated for regular clinical usage, partly due to challenges in pre-transplantation cell labelling and post-transplantation cell tracking. Amidst this, there are growing concerns over the toxicity of commonly used gadolinium-based contrast agents that mediate in-vivo cell detection via MRI. This urges to search for equally effective but less toxic alternatives that would facilitate and enhance MSC detection post-administration and provide therapeutic benefits in-vivo. MSCs labelled with iron oxide nanoparticles (IONPs) have shown promising results in-vitro and in-vivo. Thus, it would be useful to revisit these studies before inventing new labelling approaches. Aiming to inform regenerative medicine and augment clinical applications of IONP-labelled MSCs, this review collates and critically evaluates the utility of IONPs in enhancing MSC detection and therapeutics. It explains the rationale, principle, and advantages of labelling MSCs with IONPs, and describes IONP-induced intracellular alterations and consequent cellular manifestations. By exemplifying clinical pathologies, it examines contextual in-vitro, animal, and clinical studies that used IONP-labelled bone marrow-, umbilical cord-, adipose tissue- and dental pulp-derived MSCs. It compiles and discusses studies involving MSC-labelling of IONPs in combinations with carbohydrates (Venofer, ferumoxytol, dextran, glucosamine), non-carbohydrate polymers [poly(L-lysine), poly(lactide-co-glycolide), poly(L-lactide), polydopamine], elements (ruthenium, selenium, gold, zinc), compounds/stains (silica, polyethylene glycol, fluorophore, rhodamine B, DAPI, Prussian blue), DNA, Fibroblast growth Factor-2 and the drug doxorubicin. Furthermore, IONP-labelling of MSC exosomes is reviewed. Also, limitations of IONP-labelling are addressed and methods of tackling those challenges are suggested. Graphical Abstract

show abstract

Section: Current State Hurdles Future Work and Perspectivesmentioning

confidence: 99%

“…However, there are concerns over reporter genes being integrated at random sites in the genome and this may alter MSC characteristics. Again, the aim is to counteract this by using editing technologies that allow site-specific DNA integration [ 168 ].…”

Section: Current State Hurdles Future Work and Perspectivesmentioning

confidence: 99%

Iron Oxide Nanoparticles in Mesenchymal Stem Cell Detection and Therapy

Mehta

2022

Stem Cell Rev and Rep

View full text Add to dashboard Cite

show abstract

“…The HSV-1-tk system has been further elaborated in the past 15 years with regard to (i) the assessment of anti-cancer therapy paradigms [89][90][91][92], employing tumor-specific promoters [93,94], cancer-directed T-cells [95,96], transduced mesenchymal stem cells [97][98][99][100] or bone marrow-derived tumor-infiltrating progenitor cells; (ii) the visualization of tumor burden [101] and the primary anti-tumor immune response [102].…”

Section: Enzyme Gene Reporter: Hsv-1-tk Imaging Using [ 18 F]fhbg or ...mentioning

confidence: 99%

“…Platelets, T-cells and cardiomyocytes could be visualized by [ 18 F]FHBG PET imaging. There have been many trials of mesenchymal stem cells (MSCs) as cell-based drug delivery systems in which tumors homing and assessment of their therapeutic effects were monitored by transducing the cells with HSV-1-tk to allow their visualization using PET [97,103]. One of the most important clinical applications of HSV-1-tk in CAR-T cells was published by Keu et al (2017), which demonstrated that tumor-associated CD8 + engineered T lymphocytes expressing both HSV1-tk and interleukin-13 (IL-13) zetakine chimeric antigen receptor (CAR) could be tracked longitudinally by [ 18 F]FHBG imaging in patients with high-grade glioma [96] (Figure 2A).…”

Section: Enzyme Gene Reporter: Hsv-1-tk Imaging Using [ 18 F]fhbg or ...mentioning

confidence: 99%

Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy

et al. 2021

View full text Add to dashboard Cite

Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized management. While the definition of theranostics was initially restricted to a single compound allowing visualization and therapy simultaneously, the concept has been widened with the development of theranostic pairs and the combination of nuclear medicine with different types of cancer therapies. Here, we review the clinical applications of different theranostic radiopharmaceuticals in managing different tumor types (differentiated thyroid, neuroendocrine prostate, and breast cancer) that support the combination of innovative oncological therapies such as gene and cell-based therapies with RT.

show abstract

“…The optimal route of administration of hADSC for different diseases is still unknown, but many studies have chosen the peripheral venous administration route [ 38 ]. With respect to intravenous administration, information on the in vivo behavior of the cells has been partially obtained via in vivo imaging of fluorescently or radioisotope-labeled hADSC [ 39 ]. In addition, the effects of different cell preparations, manufacturing and storage protocols, and administration methods on cell viability, phenotype, and function have been investigated in human MSC [ 40 , 41 ].…”

Section: Introductionmentioning

confidence: 99%

Optimal Intravenous Administration Procedure for Efficient Delivery of Canine Adipose-Derived Mesenchymal Stem Cells

Yasumura

Teshima

Taira

et al. 2022

IJMS

View full text Add to dashboard Cite

Mesenchymal stem cells (MSC) are currently being investigated for their therapeutic applications in a wide range of diseases. Although many studies examined peripheral venous administration of MSC, few have investigated the detailed intravenous administration procedures of MSC from their preparation until they enter the body. The current study therefore aimed to explore the most efficient infusion procedure for MSC delivery by preparing and infusing them under various conditions. Canine adipose-derived mesenchymal stem cells (cADSC) were infused using different infusion apparatuses, suspension solutions, allogenic serum supplementation, infusion time and rates, and cell densities, respectively. Live and dead cell counts were then assessed by manual measurements and flow cytometry. Efficiency of live- and dead-cell infusion and cell viability were calculated from the measured cell counts and compared under each condition. Efficiency of live-cell infusion differed significantly according to the infusion apparatus, infusion rate, and combination of cell density and serum supplementation. Cell viability after infusion differed significantly between the infusion apparatuses. The optimal infusion procedure resulting in the highest cell delivery and viability involved suspending cADSC in normal saline supplemented with 5% allogenic serum at a density of 5 × 105 cells/mL, and infusing them using an automatic infusion device for 15 min. This procedure is therefore recommended as the standard procedure for the intravenous administration of ADSC in terms of cell-delivery efficiency.

show abstract

Noninvasive in vivo cell tracking using molecular imaging: A useful tool for developing mesenchymal stem cell-based cancer treatment

Cited by 10 publications

References 102 publications

Iron Oxide Nanoparticles in Mesenchymal Stem Cell Detection and Therapy

Iron Oxide Nanoparticles in Mesenchymal Stem Cell Detection and Therapy

Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy

Optimal Intravenous Administration Procedure for Efficient Delivery of Canine Adipose-Derived Mesenchymal Stem Cells

Contact Info

Product

Resources

About